LON:SBTX SkinBioTherapeutics (SBTX) Share Price, News & Analysis → Radical change coming — do this NOW to protect yourself (From Weiss Ratings) (Ad) Free SBTX Stock Alerts GBX 9.70 0.00 (0.00%) (As of 09:58 AM ET) Add Compare Share Share Today's Range 9.57▼ 1050-Day Range 8.60▼ 10.3052-Week Range 7▼ 29.50Volume1.14 million shsAverage Volume685,473 shsMarket Capitalization£19.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsStock AnalysisChartCompetitors Get SkinBioTherapeutics alerts: Email Address Ad Weiss RatingsRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and radically change life in America as we know it today. And a Draconian set of technologies that could impose a new kind of financial surveillance in America. Click here to learn more. About SkinBioTherapeutics Stock (LON:SBTX)SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.Read More SBTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SBTX Stock News HeadlinesJune 9, 2024 | americanbankingnews.comSkinBioTherapeutics (LON:SBTX) Shares Down 1.3% May 1, 2024 | ca.finance.yahoo.comSkinBioTherapeutics plc (SBTX.L)March 26, 2024 | finance.yahoo.comSkinBioTherapeutics First Half 2024 Earnings: UK£0.008 loss per share (vs UK£0.008 loss in 1H 2023)March 18, 2024 | lse.co.ukSkinBioTherapeutics announces research into wound healing bacteriumNovember 17, 2023 | uk.investing.comSkinBioTherapeutics bags £3m at a modest discountNovember 16, 2023 | marketwatch.comSkinBioTherapeutics to Raise at Least $3.7 MlnSeptember 14, 2023 | uk.investing.comFiverr International Ltd DRC (F2VR34)September 2, 2023 | uk.investing.comSocietatea de Producere a Energiei Electrice in Hidrocentrale Hidroelectrica SA (ROH2O)July 11, 2023 | finance.yahoo.comSBTX.L - SkinBioTherapeutics PlcJune 21, 2023 | marketwatch.comSkinBioTherapeutics Gets Approval for Supplement Launch in ItalyMarch 30, 2023 | finance.yahoo.comSkinBioTherapeutics Reports First Half 2023 EarningsMarch 28, 2023 | marketwatch.comSkinBioTherapeutics Shares Fall on Widened 1H Pretax Loss From Higher CostsMarch 22, 2023 | finance.yahoo.comIs SkinBioTherapeutics (LON:SBTX) In A Good Position To Invest In Growth?December 21, 2022 | marketwatch.comSkinBioTherapeutics Raises GBP2.6 Mln in Placing, Retail OfferDecember 15, 2022 | marketwatch.comSkinBioTherapeutics to Raise a Minimum of GBP2.5 MlnOctober 14, 2022 | finance.yahoo.comAfter losing 68% in the past year, SkinBioTherapeutics Plc (LON:SBTX) institutional owners must be relieved by the recent gainAugust 31, 2022 | lse.co.ukSkinBioTherapeutics shares fall as probiotic AxisBiotix-PS sales dropAugust 31, 2022 | marketwatch.comSkinBioTherapeutics Shares Fall After Worse-Than-Expected Supplement SalesJune 15, 2022 | proactiveinvestors.comSkinBioTherapeutics puzzled by share price, says feedback positive for psoriasis treatmentJune 13, 2022 | marketwatch.comSkinBioTherapeutics Knows No Reason For Share Price FallMay 20, 2022 | news.yahoo.comWhat It's Like Inside a Burning Drift CarMay 20, 2022 | news.yahoo.comReport raises concerns over lay-offs, cash flow at Cottage clinic; records issues resolvedMay 18, 2022 | finance.yahoo.comWe're Keeping An Eye On SkinBioTherapeutics' (LON:SBTX) Cash Burn RateMarch 29, 2022 | lse.co.ukSkinBioTherapeutics proposes Manprit Singh Randhawa as new CFOMarch 29, 2022 | marketwatch.comSkinBioTherapeutics Shares Drop 30% After Widened 1H Pretax LossSee More Headlines Receive SBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SkinBioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/03/2020Today6/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:SBTX CUSIPN/A CIKN/A Webwww.skinbiotherapeutics.com Phone+44-161-4682760FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,880,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-118.63% Return on Assets-61.18% Debt Debt-to-Equity Ratio2.66 Current Ratio6.57 Quick Ratio10.01 Sales & Book Value Annual Sales£21,949.00 Price / Sales885.55 Cash FlowGBX 1.08 per share Price / Cash Flow9.00 Book ValueGBX 2 per share Price / Book4.85Miscellaneous Outstanding Shares200,380,000Free FloatN/AMarket Cap£19.44 million OptionableNot Optionable Beta1.67 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Stuart John Ashman (Age 58)CEO & Executive Director Comp: $371.1kMr. Manprit Singh Randhawa (Age 41)CFO, Secretary & Director Comp: $261.48kLaura BeyHead of FormulationsMs. Melissa GreenwellGroup Financial ControllerKey CompetitorsPoolbeg PharmaLON:POLBFaron Pharmaceuticals OyLON:FARNOpen OrphanLON:ORPHRedx PharmaLON:REDXe-therapeuticsLON:ETXView All Competitors SBTX Stock Analysis - Frequently Asked Questions How have SBTX shares performed in 2024? SkinBioTherapeutics' stock was trading at GBX 15.25 at the beginning of the year. Since then, SBTX shares have decreased by 36.4% and is now trading at GBX 9.70. View the best growth stocks for 2024 here. How were SkinBioTherapeutics' earnings last quarter? SkinBioTherapeutics plc (LON:SBTX) issued its quarterly earnings results on Tuesday, March, 3rd. The company reported ($0.64) earnings per share for the quarter. What other stocks do shareholders of SkinBioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other SkinBioTherapeutics investors own include Avacta Group (AVCT), Inspired (INSE), OptiBiotix Health (OPTI), Lb-shell (LBP), Anglo African Oil & Gas (AAOG), Big Sofa Technologies Group (BST), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES) and Shield Therapeutics (STX). How do I buy shares of SkinBioTherapeutics? Shares of SBTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:SBTX) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | Sponsored"Trump Loophole" Beats InflationThe demise of the "petrodollar" appears imminent. And the implications for Americans could be dire.Colonial Metals | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SkinBioTherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share SkinBioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.